Comparison of leukotriene receptor antagonists in addition to inhaled corticosteroid and inhaled corticosteroid alone in the treatment of adolescents and adults with bronchial asthma: A meta-analysis

Asian Pacific Journal of Allergy and Immunology

Volumn 30, Issue 2, 2012, Pages 130-138

  Cao, Yong ^a   Wang, Jianmiao ^a   Bunjhoo, Hansvin ^a   Xie, Min ^a   Xu, Yongjian ^a   Fang, Huijuan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Asthma; Inhaled corticosteroid; Leukotriene receptor antagonist; Meta analysis

Indexed keywords

BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO; ZAFIRLUKAST;

ADOLESCENT DISEASE; ADULT DISEASE; ASTHMA; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LUNG FUNCTION; META ANALYSIS; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; DATABASES, BIBLIOGRAPHIC; DRUG THERAPY, COMBINATION; HUMANS; LEUKOTRIENE ANTAGONISTS; MIDDLE AGED; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT;

EID: 84863423871     PISSN: 0125877X     EISSN: 22288694     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Global Initiative for Asthma (GINA), National heart, lung, and blood institute, Bethesda, MD, 2006. Available online at www.ginasthma.org; last accessed 2009
2. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ. 2002:324:1545
3. Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax. 2008;63:453-62.
4. Vaquerizo MJ, Casan P, Castillo J, Perpiña M, Sanchis J, Sobradillo V, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax. 2003;58:204-10.
5. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone additivity group. Am J Respir Crit Care Med. 1999;160:1862-8.
6. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
7. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60 8.
8. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
9. Dempsey OJ, Fowler SJ, Wilson A, Kennedy G, Lipworth BJ. Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest. 2002;122:151-9.
10. Virchow JC Jr, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med. 2000;162:578-85.
11. Riccioni G, Vecchia RD, D'Orazio N, Sensi S, Guagnano MT. Comparison of montelukast and budesonide on bronchial reactivity in subjects with mild-moderate persistent asthma. Pulm Pharmacol Ther. 2003;16:111-4.
12. O'Sullivan S, Akveld M, Burke CM, Poulter LW. Effect of the addition of montelukast to inhaled fluticasone propionate on airway inflammation. Am J Respir Crit Care Med. 2003;167:745-50.
13. Cakmak G, Demir T, Gemicioglu B, Aydemir A, Serdaroglu E, Donma O. The effects of add-on zafirlukast treatment to budesonide on bronchial hyperresponsiveness and serum levels of eosinophilic cationic protein and total antioxidant capacity in asthmatic patients. Tohoku J Exp Med. 2004;204:249-56.
14. Djukanović R, Wilson SJ, Moore WC, Koenig SM, Laviolette M, Bleecker ER, et al. Montelukast added to fluticasone propionate does not alter inflammation or outcomes. Respir Med. 2010,104:1425-35.
15. Perng DW, Huang HY, Lee YC, Perng RP. Leukotriene modifier vs inhaled corticosteroid in mild-to-moderate asthma: clinical and anti-inflammatory effects. Chest. 2004;125:1693-9.
16. Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003;58:211-6.
17. Yildirim Z, Ozlu T, Bulbul Y, Bayram H. Addition of montelukast versus double dose of inhaled budesonide in moderate persistent asthma. Respirology. 2004;9:243-8.
18. Barnes N, Laviolette M, Allen D, Flood-Page P, Hargreave F, Corris P, et al. Effects of montelukast compared to double dose budesonide on airway inflammation and asthma control. Respir Med. 2007;101:1652-8.
19. Riccioni G, Vecchia RD, Castronuovo M, Ilio CD, D'Orazio N. Tapering dose of inhaled budesonide in subjects with mild-to-moderate persistent asthma treated with montelukast: a 16-week single-blind randomized study. Ann Clin Lab Sci. 2005;35:285-9.
20. Riccioni G, Della Vecchia R, Di Ilio C, D'Orazio N. Effect of the two different leukotriene receptor antagonists, montelukast and zafirlukast, on quality of life: a 12-week randomized study. Allergy Asthma Proc. 2004;25:445-8.
21. Riccioni G, Ballone E, D'Orazio N, Sensi S, Di Nicola M, Di Mascio R, et al. Effectiveness of montelukast versus budesonide on quality of life and bronchial reactivity in subjects with mild-persistent asthma. Int J Immunopathol Pharmacol. 2002;15:149-155.
22. Huang CJ, Wang CH, Liu WT, Yang MC, Lin HC, Yu CT, et al. Zafirlukast improves pulmonary function in patients with moderate persistent asthma receiving regular inhaled steroids: a prospective randomized control study. Chang Gung Med J. 2003;26:554-60.
23. McIvor RA, Kaplan A, Koch C, Sampalis JS. Montelukast as an alternative to low-dose inhaled corticosteroids in the management of mild asthma (the SIMPLE trial): an open-label effectiveness trial. Can Respir J. 2009,16 SupplA:11A-21A.
24. FitzGerald JM, Foucart S, Coyle S, Sampalis J, Haine D, Psaradellis E, et al. Montelukast as add-on therapy to inhaled corticosteroids in the management of asthma (the SAS trial). Can Respir J. 2009,16 SupplA:5A-14A.
25. Hallstrand TS, Henderson WR Jr. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 2010;10:60-6.
26. Sin DD, Man J, Sharpe H, Gan WQ, Man SF. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA. 2004 Jul 21;292:367-76.
27. Ng D, Salvio F, Hicks G. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2004;(2):CD002314.
28. Ducharme FM, Hicks GC. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2002;(3):CD002314.
29. Ducharme FM, Hicks GC. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma. Cochrane Database Syst Rev. 2000;(3):CD002314.
30. Philip G, Villarán C, Shah SR, Vandormael K, Smugar SS, Reiss TF. The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma. J Asthma.2011,48:495-502.